<?xml version='1.0' encoding='utf-8'?>
<document id="19487252"><sentence text="Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine."><entity charOffset="43-52" id="DDI-PubMed.19487252.s1.e0" text="efavirenz" /><entity charOffset="123-133" id="DDI-PubMed.19487252.s1.e1" text="zidovudine" /><pair ddi="false" e1="DDI-PubMed.19487252.s1.e0" e2="DDI-PubMed.19487252.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19487252.s1.e0" e2="DDI-PubMed.19487252.s1.e1" /></sentence><sentence text="The non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) is directly conjugated by the UDP-glucuronosyltransferase (UGT) pathway to form EFV-N-glucuronide (EFV-G), but the enzyme(s) involved has not yet been identified"><entity charOffset="51-60" id="DDI-PubMed.19487252.s2.e0" text="efavirenz" /><entity charOffset="147-164" id="DDI-PubMed.19487252.s2.e1" text="EFV-N-glucuronide" /><entity charOffset="166-171" id="DDI-PubMed.19487252.s2.e2" text="EFV-G" /><pair ddi="false" e1="DDI-PubMed.19487252.s2.e0" e2="DDI-PubMed.19487252.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19487252.s2.e0" e2="DDI-PubMed.19487252.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19487252.s2.e0" e2="DDI-PubMed.19487252.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19487252.s2.e1" e2="DDI-PubMed.19487252.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19487252.s2.e1" e2="DDI-PubMed.19487252.s2.e2" /></sentence><sentence text=" The glucuronidation of EFV was screened with UGT1A and UGT2B enzymes expressed in a heterologous system, and UGT2B7 was shown to be the only reactive enzyme" /><sentence text=" The apparent K(m) value of UGT2B7 (21 microM) is similar to the value observed for human liver microsomes (24 microM), whereas the variant allozyme UGT2B7*2 (Tyr(268)) displayed similar kinetic parameters" /><sentence text=" Because 3'-azido-3'-deoxythymidine (AZT), one of the most current nucleotide reverse transcriptase inhibitors prescribed in combination with EFV, is also conjugated by UGT2B7, the potential metabolic interaction between EFV and AZT has been studied using human liver microsomes"><entity charOffset="9-35" id="DDI-PubMed.19487252.s5.e0" text="3'-azido-3'-deoxythymidine" /><entity charOffset="37-40" id="DDI-PubMed.19487252.s5.e1" text="AZT" /><entity charOffset="229-231" id="DDI-PubMed.19487252.s5.e2" text="AZT" /><pair ddi="false" e1="DDI-PubMed.19487252.s5.e0" e2="DDI-PubMed.19487252.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19487252.s5.e0" e2="DDI-PubMed.19487252.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19487252.s5.e0" e2="DDI-PubMed.19487252.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19487252.s5.e1" e2="DDI-PubMed.19487252.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19487252.s5.e1" e2="DDI-PubMed.19487252.s5.e2" /></sentence><sentence text=" Glucuronidation of both drugs was inhibited by one another, in a concentration-dependent manner" /><sentence text=" At K(m) values (25 and 1000 microM for EFV and AZT, respectively), EFV inhibited AZT glucuronidation by 47%, whereas AZT inhibited EFV glucuronidation by 23%"><entity charOffset="48-50" id="DDI-PubMed.19487252.s7.e0" text="AZT" /><entity charOffset="82-84" id="DDI-PubMed.19487252.s7.e1" text="AZT" /><entity charOffset="118-120" id="DDI-PubMed.19487252.s7.e2" text="AZT" /><pair ddi="false" e1="DDI-PubMed.19487252.s7.e0" e2="DDI-PubMed.19487252.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19487252.s7.e0" e2="DDI-PubMed.19487252.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19487252.s7.e0" e2="DDI-PubMed.19487252.s7.e2" /><pair ddi="false" e1="DDI-PubMed.19487252.s7.e1" e2="DDI-PubMed.19487252.s7.e1" /><pair ddi="false" e1="DDI-PubMed.19487252.s7.e1" e2="DDI-PubMed.19487252.s7.e2" /></sentence><sentence text=" With a K(i) value of 17 microM for AZT-glucuronide formation, EFV appears to be one of the most selective and potent competitive inhibitor of AZT glucuronidation in vitro"><entity charOffset="36-51" id="DDI-PubMed.19487252.s8.e0" text="AZT-glucuronide" /><entity charOffset="143-157" id="DDI-PubMed.19487252.s8.e1" text="AZT" /><pair ddi="false" e1="DDI-PubMed.19487252.s8.e0" e2="DDI-PubMed.19487252.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19487252.s8.e0" e2="DDI-PubMed.19487252.s8.e1" /></sentence><sentence text=" Moreover, assuming that concentrations of EFV achieved in plasma (C(max) = 12" /><sentence text="9 microM) are in a range similar to its K(i) value, it was estimated that EFV could produce a theoretical 43% inhibition of AZT glucuronidation in vivo"><entity charOffset="124-126" id="DDI-PubMed.19487252.s10.e0" text="AZT" /></sentence><sentence text=" We conclude that UGT2B7 has a major role in EFV glucuronidation and that EFV could potentially interfere with the hepatic glucuronidation of AZT"><entity charOffset="142-144" id="DDI-PubMed.19487252.s11.e0" text="AZT" /></sentence><sentence text="" /></document>